Your shopping cart is empty

Subscriber login

REGISTER FOR FREE EZINES

Advanced Search

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

E-Zines

Check out our free and informative ezines and sign up now

Home > Newsletters > FDAnews Drug Daily Bulletin > Pfizer’s Wyeth Ordered to Face Class-Action Over Pristiq

FDAnews Drug Daily Bulletin

Sept. 20, 2012 | Vol. 9 No. 185

Pfizer’s Wyeth Ordered to Face Class-Action Over Pristiq

A federal judge has granted class-action status to former Wyeth shareholders who accused the company, now part of Pfizer, of misleading them about risks associated with the antidepressant Pristiq.
Reuters

Register Now
Print This Page
Email This Article
RSS
Archives

Related Articles

Pharma Blog Watch Prices of Pharmaceuticals Likely to Increase in Pakistan Teva Stops Filing For Patents in Israel; Will File for Them in Switzerland Instead U.S. Court Finds Novo Nordisk Prandin Diabetes Drug Patent Invalid

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.

ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnews

All rights reserved. Do not duplicate or redistribute in any form.